Switch in Immunocompromised Japanese Pediatric Patients 2

Department of Pediatrics, Yokohama City University Medical Center, Yokohama, 6 Japan; Department of Pediatrics, Sapporo Hokuyu Hospital, Sapporo, Japan; 7 Department of Hematology and Oncology, Children's Medical Center, Japanese Red 8 Cross Nagoya First Hospital, Nagoya, Japan; Department of Pediatrics, National 9 Hospital Organization Nagoya Medical Center, Nagoya, Japan; Department of 10 Pediatrics, Dokkyo Medical University School of Medicine, Tochigi, Japan; 11 Department of Hematology and Regenerative Medicine, Kanagawa Children's 12 Medical Center, Kanagawa, Japan; Department of Hematology/Oncology, Osaka 13 Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan; 14 Clinical Pharmacology, Clinical Research, Pfizer Japan Inc, Tokyo, Japan; Clinical 15 Statistics, Development Operations, Pfizer Japan Inc, Tokyo, Japan; Infectious 16 disease, Clinical Research, Pfizer Japan Inc, Tokyo, Japan; Clinical Pharmacology, 17 Global Established Pharma Business, Pfizer Inc, Groton, CT, USA 18